Clinical trials: Candidiasis, Invasive
Invasive Candidiasis
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)
- Trial name
- NCT00250432
- Testing
- caspofungin acetate
- Volunteers
- 204 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidiasis
A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China
The incidence of invasive candida infection (ICI) in critically ill patients is increasing day by day. The crude mortality of IFI in ICU could be as high as 25%-75% depending on their age, underlying conditions, and so on.
- Trial name
- china-scan (NCT01253954)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Southeast University, China
Invasive Candidiasis
Invasive Candidiasis in Saudi ICUs
Epidemiology and clinical outcomes of invasive candidiasis in critically ill patients in Saudi Arabia is not well studied. This observational study objectives include to determine the epidemiology, risk factors and outcomes of…
- Trial name
- ICIP-SA (NCT01490684)
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 162 people
- Sponsor
- Hasan Al-Dorzi
Fungal Infection
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
To evaluate the safety, tolerability, and efficacy of caspofungin for the treatment of esophageal candidiasis and invasive candidiasis to support the registration of caspofungin for these indications in China.
- Trial name
- NCT00635648
- Testing
- caspofungin acetate
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Candidemia
Risk Factor and Outcome of Candidemia
Candidemia is the fourth leading cause of hospital-acquired infection in USA. In CMUH, it caused 9% hospital-acquired bloodstream infection in 2008 and 2009.
- Trial name
- NCT01249313
- Volunteers
- 1,000 people
- Sponsor
- China Medical University Hospital
Invasive Candidiasis
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Adults admitted to intensive care units are at risk for a variety of complications. Infections due to the fungus called candida are of particular concern.
- Trial name
- MSG-01 (NCT00520234)
- Testing
- Caspofungin, Normal Saline
- Where
- 12 sites in United States
- Volunteers
- 222 people
- Sponsor
- Mycoses Study Group
Candidemia
Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital
During the past two decades, the frequency of invasive fungal infections has increased dramatically in hospitalised patients throughout the world, and Candida has now emerged as one of the leading causes of bloodstream infections…
- Trial name
- NCT00903526
- Volunteers
- 250 people
- Sponsor
- University of Modena and Reggio Emilia
Aspergillosis, Candidiasis
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
The objective of this study is to evaluate the efficacy, safety and toleration of voriconazole in the primary treatment of systemic or invasive fungal infections due to fungal pathogens for which there is no licensed therapy; and…
- Conditions
- Aspergillosis, Candidiasis, Fungemia, Mycoses
- Trial name
- NCT00001810
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Invasive Candidiasis
Comparison of Uncomplicated Candidemia Therapy Duration in Children
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: Compare the desirability of outcome ranking in children with uncomplicated candidemia…
- Trial name
- COUNT (NCT05763251)
- Testing
- therapy duration
- Where
- 22 sites in United States, Australia
- Volunteers
- 420 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Candidiasis
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
The purpose of the study is to evaluate the safety and efficacy of FK463 in the treatment of patients with confirmed candidemia or invasive candidiasis.
- Trial name
- NCT00036179
- Testing
- FK463
- Where
- 23 sites in Austria, France and 6 more
- Volunteers
- 75 people
- Sponsor
- Astellas Pharma Inc
Candidemia, Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
- Trial name
- CRITIC (NCT00670657)
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Gilead Sciences
Invasive Candidiasis
Variability of Fluconazole Concentration in Critically Ill Patients
Fluconazole is the first-line agent in the treatment of invasive candidiasis. Studies showed inappropriate drug exposure causes high mortality in critically ill patients.
- Trial name
- NCT02491151
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Candidemia
A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
This study will evaluate the incidence rate of Candida blood stream infection (candidemia) among people hospitalized in participating medical centers in Brazil, and will assess the antifungal drug susceptibility patterns of…
- Trial name
- NCT01174147
- Volunteers
- 436 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Candidiasis, Candidemia
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin…
- Trial name
- NCT01213823
- Testing
- Does not apply
- Volunteers
- 536 people, healthy volunteers welcome
- Sponsor
- Pfizer
Candidemia
Early- and Late-onset Candidemia
A timing diagnosis of candidemia is as important as the correct choice of empiric or targeted antifungal therapy. In the last years a growing body of knowledge has better characterized health-care associated (HCA) infections…
- Trial name
- NCT01406093
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Giovanni Di Perri
Mycoses
Voriconazole to Treat Fungal Infections
Voriconazole is a new drug developed to treat fungal infections. As of March 1999, the drug had been studied in more than 1,900 healthy volunteers or patients with fungal infections.
- Trial name
- NCT00001940
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Candidemia
Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
The purpose of this study is to assess the feasibility and preliminary efficacy of interferon-gamma in combination with anidulafungin for the treatment of candidemia
- Trial name
- NCT01270490
- Testing
- Interferon-gamma, Recombinant
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Invasive Candidiases, Abdominal Infection
A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis
This is a multicenter, prospective, open-label, randomized trial. Patients with severe abdominal condition developing severe sepsis or septic shock and receiving broad spectrum antibiotic and antifungal treatment will be…
- Trial name
- NCT03090334
- Testing
- De-escalation
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Bologna
Candida Systemic, Candida Albicans Infection
Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement
This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete…
- Conditions
- Candida Systemic, Candida Albicans Infection, Candida Infection
- Trial name
- NCT06146504
- Testing
- CanXida Remove (Formula RMV)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CanXida